For Immediate Release
Chicago, IL – March 1, 2012 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Dendreon Corporation , Merck, Inc. ( (MRK - Analyst Report), Johnson & Johnson ( (JNJ - Analyst Report), Medivation (MDVN - Analyst Report) and CONSOL Energy Inc. ( (CNX - Analyst Report).
Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=5513
Here are highlights from Wednesday’s Analyst Blog:
Bleak Outlook for Dendreon’s Provenge
Dendreon Corporation reported fourth-quarter 2011 earnings (including stock-based compensation expense but excluding other special items) of 37 cents per share, in contrast to the Zacks Consensus Estimate loss of 31 cents and year-ago loss of 60 cents per share.
Full-year loss of $1.68 per share (excluding special items but including stock-based compensation expense) were narrower than the Zacks Consensus Estimate of a loss of $2.83 and the year-ago loss of $3.07 per share.
Total revenue in the reported quarter climbed to $202.1 million from $25.0 million in the comparable quarter of 2010. We note, however, that revenue in the reported quarter included one-time royalty revenue of $125 million related to sale of its royalty interest in Merck, Inc.’s ( (MRK - Analyst Report) hepatitis C product Victrelis.
Excluding this one-time revenue, Dendreon recorded revenues of $77 million. The Zacks Consensus Estimate was at $113 million. Full-year revenues at $341.6 million were above the year-ago revenues of $48.1 million. The Zacks Consensus full-year estimate was at $259 million.
Quarter in Details
Dendreon reported net Provenge revenue of $77.0 million in the fourth quarter up from $25.0 million in the comparable quarter of 2010. However, we note that earlier on January 5, 2012, during pre-announcement of fourth quarter results, management declared gross product revenue of approximately $82 million.
Research & development (R&D) expenses were $18 million, reflecting a year-over-year increase of 50%. Selling, general & administrative (SG&A) expenses for the fourth quarter decreased 11.3% to $76 million.
For the full year 2011, Dendreon reported net Provenge revenue of $214 million. Full-year sales of Provenge was, however, well below the company’s original forecast, in a band of $350 million – $400 million, which was withdrawn last year on dismal performance of the vaccine.
Despite a favorable reimbursement environment for the vaccine, Dendreon faced tough times in 2011 as Provenge sales failed to live up to the expectations of the management and the investors. Provenge’s high cost density had been eluding physician acceptance of the vaccine. Other problems which were affecting the sales of the vaccine included lack of easy access to Provenge and inability on the part of physicians to identify eligible patients for Provenge treatment.
According to management awareness gradually improves on the favorable reimbursement environment. The physicians are more comfortable with prescribing Provenge as the average time to payment for physicians has come down to less than 30 days.
Moreover, management pointed out that out of pocket expenses were negligible for almost 75% of the patients on Provenge treatment. Dendreon reported that the number of centers where patients can be treated with Provenge increased from 425 at the end of the third quarter 2011 to 590 centers at the end of 2011. So far, the company has added another 80 sites in 2012.
Management announced that the European Medicines Agency (EMA) accepted the marketing authorization application (MAA) for Provenge, submitted by the company in January 2012.
Dendreon expects to post modest quarter-over-quarter growth in 2012.
In the first quarter 2012 the company expects to see moderate single digit growth in Provenge sales. The company said the there was some pull through of January sales in December, of approximately $2 million to $3 million, as patients want have their treatment completed by the year-end holidays.
The company expects to achieve cash breakeven at $125 million net revenue each quarter or annual net revenue to be $500 million. At this level of net revenues, the company expects to reduce the cost of goods sold to 50% from the current 70% range. The company expects to reduce cost of goods sold further to 20% – 30% by 2014.
The company expects 2012 R&D expenses to be approximately $100 million. The expenses are expected to be higher in the first two quarters than later in the year. Fourth quarter R&D expenditure is expected to be around $20 million.
In 2012, SG&A expenses are expected to decrease throughout the year, primarily as a result of a reduction in non-cash deferred compensation. Fourth quarter SG&A expenses are expected to be around $70 million.
We currently have a Neutral recommendation on Dendreon. The stock carries a Zacks #3 Rank (Hold rating) in the short run.
The successful commercialization of Provenge is crucial for the financial performance of Dendreon as it can drive the company to profitability. Though we are concerned about the expected discouraging growth of Provenge in the first quarter 2012 and prefer to remain on the sidelines until we get better visibility on whether the improvement in Provenge’s sales is sustainable.
We are also concerned about the competition faced by Provenge from Johnson & Johnson ( (JNJ - Analyst Report) Zytiga which was launched in the second quarter of 2011 and is doing reasonably well. Moreover, Medivation’s (MDVN - Analyst Report) pipeline candidate, MDV3100, generated positive data in the beginning of 2012 which showed that the AFFIRM study met all the primary and secondary endpoints with statistical significance. MDV3100, if approved, could pose stiff competition to Provenge.
In the long run, we remain concerned about the company’s dependence on Provenge and the lack of a decent pipeline. We believe Dendreon has little to fall back on if Provenge further belies expectations.
CNX Shuts Mine on Low Nat Gas Price
Coal and natural gas producer, CONSOL Energy Inc. ( (CNX - Analyst Report) has decided to temporarily shut down its Northern West Virginia Blacksville No. 2 longwall mining unit and has also planned to reduce its continuous mining operating schedule to 4 days per week. The move comes in the wake of sustained low natural gas prices that evinced higher demand. Also, the demand for coal has dwindled in cahoots with mild winter weather.
Additionally, we believe that a coal producer has to face increasing competition from renewable energy producers as some states have laid down policies for generation of energy from renewable sources and, as a consequence, producers with a renewable energy portfolio are gaining prominence. This would be one more reason for the short-term closure. As a consequence, CONSOL’s monthly production will be reduced by approximately 400,000 tons per month.
At its earnings call, in January this year, CONSOL had indicated that it expects coal production to be in the respective range of 15.5–15.9 million tons and 59.5 − 61.5 million tons in the first quarter and full year 2012. However, as a result of the shut down, we do not expect the company to meet its guidance.
The company indicated that there would be no layoffs and added overtime and other non-essential work will be delayed as a result of the temporary shutdown. The company has not indicated any timeframe for the closure. In 2011, the mine produced 4.3 million tons of coal utilizing a single longwall and 3 continuous mining units.
Want more from Zacks Equity Research? Subscribe to the free Profit from the Pros newsletter: http://at.zacks.com/?id=5515.
About Zacks Equity Research
Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.
Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today: http://at.zacks.com/?id=5517
Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leon Zacks. As a PhD from MIT Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros at http://at.zacks.com/?id=5518.
Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Follow us on Twitter: http://twitter.com/zacksresearch
Join us on Facebook: http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts
Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.
Zacks Investment Research
800-767-3771 ext. 9339